{
    "root": "23ebfa5b-992a-4847-b6d3-8d62da976ba8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ojjaara",
    "value": "20230915",
    "ingredients": [
        {
            "name": "MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE",
            "code": "LDX8893L5D"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A CORN",
            "code": "AG9B65PV6B"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "PROPYL GALLATE",
            "code": "8D4SNN7V92"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "ojjaara indicated treatment intermediate high-risk myelofibrosis ( mf ) , including primary mf secondary mf [ post-polycythemia vera ( pv ) post-essential thrombocythemia ( et ) ] , adults anemia .",
    "contraindications": "\u2022 recommended : 200 mg orally daily without food . ( 2.1 ) \u2022 severe hepatic impairment ( child-pugh class c ) : reduce starting dose 150 mg orally daily . ( 2.3 )",
    "warningsAndPrecautions": "ojjaara ( momelotinib ) tablets available follows : table 6 : ojjaara presentations ndc number strength description tablets per bottle ndc 81864-103-30 100 mg round-shaped brown film-coated tablet \u201c \u201d one side \u201c 100 \u201d side . 30 ndc 81864-102-30 150 mg triangular-shaped brown film-coated tablet \u201c \u201d one side \u201c 150 \u201d side . 30 ndc 81864-101-30 200 mg capsule-shaped brown film-coated tablet \u201c \u201d one side \u201c 200 \u201d side . 30 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . dispense patient original bottle . store original bottle protect moisture . replace cap securely time opening . discard desiccant .",
    "adverseReactions": "none .",
    "indications_original": "OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.",
    "contraindications_original": "\u2022 Recommended dosage: 200\u00a0mg orally once daily with or without food. ( 2.1 ) \u2022 Severe hepatic impairment (Child-Pugh Class C): Reduce the starting dose to 150\u00a0mg orally once daily. ( 2.3 )",
    "warningsAndPrecautions_original": "OJJAARA (momelotinib) tablets are available as follows:\n                  \n                     Table\u00a06: OJJAARA Presentations\n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 NDC Number\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Description\n                              \n                           \n                           \n                              \n                                 Tablets per Bottle\n                              \n                           \n                        \n                        \n                           \n                              NDC 81864-103-30\n                           \n                           \n                              100\u00a0mg\n                           \n                           \n                              Round-shaped brown film-coated tablet with \u201cM\u201d on one side and \u201c100\u201d on the other side.\n                           \n                           \n                              30\n                           \n                        \n                        \n                           \n                              NDC 81864-102-30\n                           \n                           \n                              150\u00a0mg\n                           \n                           \n                              Triangular-shaped brown film-coated tablet with \u201cM\u201d on one side and \u201c150\u201d on the other side.\n                           \n                           \n                              30\n                           \n                        \n                        \n                           \n                              NDC 81864-101-30\n                           \n                           \n                              200\u00a0mg\n                           \n                           \n                              Capsule-shaped brown film-coated tablet with \u201cM\u201d on one side and \u201c200\u201d on the other side.\n                           \n                           \n                              30\n                           \n                        \n                     \n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Dispense to patient in original bottle only. Store in original bottle to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant.",
    "adverseReactions_original": "None."
}